(AOF) – Carmat is launching a capital increase for an initial amount of 15 million euros as part of its short-term financing. The designer of the artificial heart expects the extension of its financial horizon until the beginning of May 2024, in the event of completion of the initial capital increase “excluding extension clause and over-allotment option”. After the offer, Carmat’s financing requirement over 12 months will be 37 to 55 million euros
This operation will be carried out by way of a public offer with elimination of preferential subscription rights. The initial amount may be increased up to 17.25 million euros in the event of full exercise of the extension clause and up to 19.8 million in the event of full exercise of the extension clause and the over-allotment option.
The subscription price is 3.99 euros per share, i.e. a discount of 30% compared to the average volume-weighted average price of the last five trading sessions preceding the setting of this subscription price. Subscription is open from January 18 to 25, 2024 inclusive.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.